Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

Αντώνιος Καρανάσος, Cihan Şimşek, Patrick W. Serruys, Jürgen Ligthart, Karen Witberg, Robert‐Jan van Geuns, George Sianos, Felix Zijlstra, Evelyn Regar

Circulation

Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial

Abstract

Discussion(0)

Related publications

Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial

Five-year follow-up of the ABSORB bioresorbable everolimus-eluting vascular scaffold system: multimodality imaging assessment

TCT-619 ABSORB Cohort B Trial: Five Year Angiographic Results Of The ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold

TCT-62 Five-Year Clinical Outcomes With Everolimus-Eluting Bioresorbable Scaffolds: Results From the Randomized ABSORB II Trial

Five-Year Optical Coherence Tomography Follow-Up of an Everolimus-Eluting Bioresorbable Vascular Scaffold